Company
Dizal
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
1
Approvals since 2021
1
Originals and new uses
Phase 3 trials
5
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Zegfrovy approved NovelBreakthrough therapyAccelerated approvalPriority reviewJul 2, 2025
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical SurgeryPivotal-lookingRecruiting
Dizal (Jiangsu) Pharmaceutical Co., Ltd.Industry
NCT07182682 · 360 participants (planned) · Start Dec 1, 2025 · Primary completion Sep 2029
Drug: sunvozertinib; Matching Placebo · For: Non-Small Cell Lung Cancer
Sites: Beijing, China; Changchun, China; Changsha, China · 49 sites in all
- A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)Pivotal-lookingRecruiting
Dizal PharmaceuticalsIndustry
NCT07139873 · 250 participants (planned) · Start Sep 8, 2025 · Primary completion Jan 2029
Drug: DZD8586; Bendamustine and 2 more · For: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sites: Nanjing, China; Tianjin, China
- A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)Pivotal-lookingRecruiting
Dizal PharmaceuticalsIndustry
NCT07234162 · 218 participants (planned) · Start May 13, 2024 · Primary completion Nov 30, 2027
Drug: Golidocitinib; Chidamide and 1 more · For: Peripheral T-cell Lymphoma
Sites: Hefei, China; Beijing, China; Chongqing, China · 51 sites in all
Marketed drugs (1)
Newest FDA action first.
- Zegfrovy Sunvozertinib · 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.